Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC Ads Reference To Alternative Treatments Urged In Health Affairs Article

This article was originally published in The Tan Sheet

Executive Summary

FDA should require that direct-to-consumer advertisements for pharmaceuticals mention alternative treatments "by name or at least by class," an article in the March/April issue of Health Affairs states.

You may also be interested in...



Citizen petitions

More than 40 citizen petitions and petitions for stay or reconsideration relating to OTCs, supplements and functional foods filed with FDA between Jan. 1, 2000 and March 2, 2001. Among issues raised, FDA agrees in recent letter with C.B. Fleet's request that bisacodyl, in enema dosage form and as part of bowel cleansing kits, be included in OTC laxative final monograph. Agency previously had concluded data support ingredient's classification as Category I (1"The Tan Sheet" March 13, 2000, p. 16). Pending petition filed by Braintree Labs in August seeks reclassification of sodium phosphate bowel preparations to Rx-only status. In April 6 petition, Lachman Consultant Services requests ANDA suitability determination for nizatidine 75 mg capsules. The listed drug, Whitehall-Robins' Axid AR, comes in tablet form. Absent a pediatric extension, Whitehall loses exclusivity April 1

Citizen petitions

More than 40 citizen petitions and petitions for stay or reconsideration relating to OTCs, supplements and functional foods filed with FDA between Jan. 1, 2000 and March 2, 2001. Among issues raised, FDA agrees in recent letter with C.B. Fleet's request that bisacodyl, in enema dosage form and as part of bowel cleansing kits, be included in OTC laxative final monograph. Agency previously had concluded data support ingredient's classification as Category I (1"The Tan Sheet" March 13, 2000, p. 16). Pending petition filed by Braintree Labs in August seeks reclassification of sodium phosphate bowel preparations to Rx-only status. In April 6 petition, Lachman Consultant Services requests ANDA suitability determination for nizatidine 75 mg capsules. The listed drug, Whitehall-Robins' Axid AR, comes in tablet form. Absent a pediatric extension, Whitehall loses exclusivity April 1

Citizen petitions

More than 40 citizen petitions and petitions for stay or reconsideration relating to OTCs, supplements and functional foods filed with FDA between Jan. 1, 2000 and March 2, 2001. Among issues raised, FDA agrees in recent letter with C.B. Fleet's request that bisacodyl, in enema dosage form and as part of bowel cleansing kits, be included in OTC laxative final monograph. Agency previously had concluded data support ingredient's classification as Category I (1"The Tan Sheet" March 13, 2000, p. 16). Pending petition filed by Braintree Labs in August seeks reclassification of sodium phosphate bowel preparations to Rx-only status. In April 6 petition, Lachman Consultant Services requests ANDA suitability determination for nizatidine 75 mg capsules. The listed drug, Whitehall-Robins' Axid AR, comes in tablet form. Absent a pediatric extension, Whitehall loses exclusivity April 1

Related Content

Topics

UsernamePublicRestriction

Register

PS090956

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel